IFP Advisors Inc raised its holdings in shares of Chemours Company (The) (NYSE:CC) by 97.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,977 shares of the specialty chemicals company’s stock after buying an additional 5,903 shares during the quarter. IFP Advisors Inc’s holdings in Chemours Company (The) were worth $606,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Financial Architects Inc increased its position in shares of Chemours Company (The) by 1,230.3% during the second quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock valued at $111,000 after purchasing an additional 2,719 shares during the period. Acrospire Investment Management LLC increased its position in shares of Chemours Company (The) by 3.4% during the second quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock valued at $117,000 after purchasing an additional 100 shares during the period. Benjamin F. Edwards & Company Inc. increased its position in shares of Chemours Company (The) by 2,138.8% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock valued at $118,000 after purchasing an additional 2,973 shares during the period. Smithfield Trust Co. increased its position in shares of Chemours Company (The) by 521.4% during the second quarter. Smithfield Trust Co. now owns 4,791 shares of the specialty chemicals company’s stock valued at $182,000 after purchasing an additional 4,020 shares during the period. Finally, Alps Advisors Inc. bought a new stake in shares of Chemours Company (The) during the second quarter valued at approximately $202,000. Institutional investors own 73.23% of the company’s stock.

In other news, VP Amy Trojanowski sold 2,500 shares of the stock in a transaction on Friday, August 11th. The stock was sold at an average price of $46.03, for a total transaction of $115,075.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider E Bryan Snell sold 10,000 shares of the stock in a transaction on Friday, August 11th. The stock was sold at an average price of $46.24, for a total value of $462,400.00. The disclosure for this sale can be found here. Insiders have sold 77,142 shares of company stock worth $3,953,265 in the last 90 days. Company insiders own 1.14% of the company’s stock.

A number of analysts have recently issued reports on the company. Zacks Investment Research cut Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. UBS AG upgraded Chemours Company (The) from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $36.00 to $50.00 in a research report on Monday, August 7th. J P Morgan Chase & Co boosted their price objective on Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a research report on Friday, August 4th. Argus restated a “buy” rating and set a $55.00 price objective (up from $50.00) on shares of Chemours Company (The) in a research report on Thursday, August 10th. Finally, Jefferies Group LLC restated a “buy” rating and set a $50.00 price objective (up from $48.00) on shares of Chemours Company (The) in a research report on Thursday, July 13th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $53.88.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/chemours-company-the-cc-shares-bought-by-ifp-advisors-inc/1682904.html.

Shares of Chemours Company (CC) opened at $52.16 on Monday. Chemours Company has a 1 year low of $16.39 and a 1 year high of $58.08. The firm has a market capitalization of $9,658.11, a price-to-earnings ratio of 18.50, a price-to-earnings-growth ratio of 0.93 and a beta of 3.59. The company has a debt-to-equity ratio of 5.07, a current ratio of 2.19 and a quick ratio of 1.63.

Chemours Company (The) (NYSE:CC) last announced its quarterly earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.11. Chemours Company (The) had a return on equity of 116.80% and a net margin of 4.86%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.59 billion. During the same period in the prior year, the business posted $0.61 earnings per share. The business’s revenue was up 13.3% compared to the same quarter last year. equities research analysts anticipate that Chemours Company will post 3.63 EPS for the current fiscal year.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.